CN109700811A - Indoleacetamide structure type androgen receptor antagonists and its application - Google Patents
Indoleacetamide structure type androgen receptor antagonists and its application Download PDFInfo
- Publication number
- CN109700811A CN109700811A CN201910125847.5A CN201910125847A CN109700811A CN 109700811 A CN109700811 A CN 109700811A CN 201910125847 A CN201910125847 A CN 201910125847A CN 109700811 A CN109700811 A CN 109700811A
- Authority
- CN
- China
- Prior art keywords
- compound
- androgen receptor
- antagonist
- pharmaceutical composition
- receptor antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940123407 Androgen receptor antagonist Drugs 0.000 title claims abstract description 24
- 239000003936 androgen receptor antagonist Substances 0.000 title claims abstract description 10
- VBHFPIWVTVHWES-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetamide Chemical group C1=CC=C2NC(CC(=O)N)=CC2=C1 VBHFPIWVTVHWES-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 208000023958 prostate neoplasm Diseases 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 230000002634 anti-blastic effect Effects 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 19
- 230000003042 antagnostic effect Effects 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 10
- 102000001307 androgen receptors Human genes 0.000 abstract description 9
- 108010080146 androgen receptors Proteins 0.000 abstract description 9
- 239000005557 antagonist Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000027455 binding Effects 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000003032 molecular docking Methods 0.000 description 10
- 238000003041 virtual screening Methods 0.000 description 9
- 230000003993 interaction Effects 0.000 description 8
- 239000003098 androgen Substances 0.000 description 7
- 238000002875 fluorescence polarization Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 238000009167 androgen deprivation therapy Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- -1 small molecule compound Chemical class 0.000 description 4
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229960000997 bicalutamide Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000009261 endocrine therapy Methods 0.000 description 3
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 3
- 238000000329 molecular dynamics simulation Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- JMEYDSHPKCSIJC-UHFFFAOYSA-N 1-[4-[2-[4-[1-[3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl]phenoxy]ethyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CCOC1=CC=C(C2CCN(CC2)C=2CCC=3N(C(=NN=3)C(F)(F)F)N=2)C=C1 JMEYDSHPKCSIJC-UHFFFAOYSA-N 0.000 description 1
- NQMUGNMMFTYOHK-UHFFFAOYSA-N 1-methoxynaphthalene Chemical compound C1=CC=C2C(OC)=CC=CC2=C1 NQMUGNMMFTYOHK-UHFFFAOYSA-N 0.000 description 1
- GMBPVBVTPBWIKC-NSHDSACASA-N 3-acetyl-n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-1h-pyrazole-5-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)=O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 GMBPVBVTPBWIKC-NSHDSACASA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This divisional application discloses indoleacetamide structure type androgen receptor antagonists and its application, belongs to technological field of biochemistry.2 kinds of compounds provided by the invention have apparent antagonistic activity to androgen receptor, therefore above compound can be applied in the preparation of androgen receptor antagonists, prostate gland cancer cell antiblastic and anti-prostate tumor drug.Pharmaceutical composition the present invention also provides above compound as effective component, the drug research for treatment prostate cancer at present provide new selection.
Description
The application is application number 201710117698.9, on March 2017 applying date 1, " androgen receptor is short of money for denomination of invention
The divisional application of anti-agent and its application ".
Technical field
The present invention relates to technological field of biochemistry, and in particular to androgen receptor antagonists and its application.
Background technique
Prostate cancer is the second largest fatal tumor of male in western countries, and recently as our people's living standard
Raising and dietary structure variation, the trend obviously increased is presented in the disease incidence of domestic prostate cancer.It is (early for Limited-stage
Phase) patients with prostate cancer, Prostate Cancer after Radical, radiotherapy can reach good therapeutic effect.But due to prostate cancer early clinic symptom
The concealment of the unobvious, state of an illness, in addition screening is not popularized, when many patient assessments, has been in the advanced stage that tumour has shifted, at this time
Prostate Cancer after Radical and chemotherapy are difficult to obtain ideal effect, it is necessary in addition use endocrine therapy.For hormone-sensitive type evening
Phase patients with prostate cancer, endocrine therapy are essential therapeutic arsenals, including operation castration, medical castration and use are with androgen receptor
Antiandrogen drug based on body (Androgen Receptor, AR) antagonist；For having progressed to the prostate of repellence
Cancer (Castration-resistant Prostate Cancer, CRPC) patient, AR antagonist be important treatment means it
One.
AR antagonist (antiandrogen) in the treatment of prostate cancer application have the long period history, initially with change
It is similar to learn castration drug gonadotropin-releasing hormone (GRH) (Luteinizing Hormone Releasing Hormone, LHRH)
Internet of Things are used, as one of Androgen deprivation therapy (Androgen Deprivation Therapy, the ADT) means of supplementing out economy,
Its main function is that disease symptoms aggravate caused by blocking medicine castration initial stage patient's body testosterone levels increase in short term.
AR antagonist can be divided into steroid and nonsteroidal by structure type；Steroid antagonist due to there are hepatotoxicity wind agitation,
Interfere sexual desire, cardiovascular side effects and it is inefficient the defects of, clinical use is limited；And the clinical use of nonsteroidal antagonist is from upper
Since century the eighties, there is first generation antagonist Flutamide, alpha..alpha..alpha.-Trifluoro-2-methyl-4'-nitro-m-lactotoluidide, Bicalutamide, Nilutamide and
The two miscellaneous Shandong amine of generation antagonist grace.Studies have shown that AR and its leading signal transduction pathway are sent out in the progression of prostate cancer
Critical effect is waved, the endocrine therapy of advanced prostate cancer is also primarily directed in this.Castration can be as far as possible
The main source for cutting off patient's body androgen makes AR lack the combination of native ligand to inhibit the access；AR antagonist then may be used
Acted on to reduce the Pathway Activation of androgen in other sources of patient's body by competitively being combined AR with androgen, from
And reach complete hormone ablative effect.Just because of this, AR antagonist was also approved as single medication later makes in ADT
With.
First generation nonsteroidal antagonists are derivative by Flutamide and go out, therefore have similar structural framework；Bicalutamide
Outstanding person best as wherein tolerance, most stable and the most widely used, in addition to can competitive binding AR be at it is short of money
Anti- state and be difficult to assemble the co-activation factor, in conjunction with DNA outside, moreover it is possible to play cancer resistant effect by reducing the stability of AR.Such as
Fruit says that first generation AR antagonist only plays limited secondary utility in the treatment of prostate cancer, then second generation antagonist grace is miscellaneous
AR antagonist has then been shifted onto the new critical role of CRPC standard care by the appearance of Shandong amine.Compared with Bicalutamide, the miscellaneous Shandong of grace
Amine has higher affinity to AR, to bring stronger drug effect；It is removed on mechanism of action and has first generation nonsteroidal antagonists
Except characteristic, it can also inhibit the nuclear transfer of AR, be allowed to that the effect that core plays transcription factor cannot be entered.The miscellaneous Shandong amine of grace initially in
It is approved within 2012 the treatment for the CRPC patient that cancer has been spread after endocrinotherapy and chemotherapy, further in 2014
It is approved for ADT treatment failure but does not receive the treatment of asymptomatic or light symptoms the metastatic CRPC of chemotherapy；As it can be seen that
Advanced metastatic CRPC available for rare drug, the miscellaneous Shandong amine of AR antagonist grace of new generation of energy independent medication, which has, lifts foot
The heavy pound medicine status of weight；And with further clinical research, therapeutic domain continues to expand in prostate cancer.
However, as the progress of disease always generates drug resistance, AR antagonist produces after each prostate cancer drug use
The concrete reason of raw drug resistance not yet illustrates completely at present, and a large amount of research observes that the mutation of AR albumen is wherein very crucial
A bit.The point mutation of AR albumen can not only make antagonist fail, but also will lead to the small molecule function for once playing antagonism
Can reverse and generate agonist effect, have even if in curative effect two generation antagonists of unique advantage after a period of use can not keep away
The meeting exempted from takes a turn for the worse effect.Therefore, of new generation, to AR high-affinity, have AR antagonist skeleton knot different from the past
The Novel antagonists molecule of structure is still the emphasis direction of prostate cancer drug research, and there is also urgent clinical demands.
Clinic mainly has ARN-509, ODM-201 and AZD3514 in the AR antagonist pharmaceuticals of new generation ground, the above two are respectively
For receiving different therapy and prostate patient in different phase is at present respectively to the phase iii clinical trial stage,
It is expected to very much granted in the near future and treatment ranks is added.ARN-509 has the structure closely similar with the miscellaneous Shandong amine of grace, mesh
Preceding result of study shows that compared with the miscellaneous Shandong amine of grace, it has a stronger receptor binding capacity, the dosage for needing to take relatively compared with
It is low, and have lower central nervous system infiltration with cause epilepsy side effect, but just because of structure excessive similarity, for grace
There is miscellaneous Shandong amine the F876L mutation of drug resistance equally can generate drug resistance to ARN-509.ODM-201 and its cylinder metabolism-ure
ORM-15341 has more novel chemical structure, its mechanism of action is similar to two generation antagonists, but very to the affinity of AR
To more than ARN-509 and the miscellaneous Shandong amine of grace.
The research situation of domestic and international AR antagonist is summarized it can be found that exploitation targets the site HBP and has novel framework knot
Structure, high-affinity and highly selective antagonist of new generation are still the emphasis of research, with the aggravation of the problem of an aging population,
There is huge clinical demands.The non-HBP antagonist for targeting other regions of AR albumen, can overcome traditional antagonist drug resistance
Defect, there are still very big clinical blank for this aspect research；The drug development of new A R antagonist shoulders heavy responsibilities.
Summary of the invention
The object of the present invention is to provide with the active compound of androgen receptor antagonist, androgen receptor is applied it to
Antagonist, anti-prostate tumor drug preparation in.
The present invention is achieved through the following technical solutions above-mentioned purpose:
The present invention has found guide's chemical combination of targeting androgen receptor using the means of Computeraided drug design
Object, then the virtual screening based on molecular docking is carried out to multiple small molecule compound three-dimensional structure databases, it is forward to obtain score
1000 compounds (energy is lower, and score is more forward).Pass through the MTT cell of prostate cancer classics cell strain LNCaP later
Proliferation experiment, the Inhibition test of AR transcription factor activity and use kit PolarScreenTM AR Competitor
Assay, Green (Thermo Fisher Scientific) investigate the combination situation of compound and the ligand binding domain LBP of AR,
Finishing screen obtains 2 representative reactive compounds, is respectively as follows:
N- (2- (1H- indoles -1- base) ethyl) -2- (the oxo piperazine -2- base of 1- (naphthalene -1- methyl) -3-) acetamide, structure
Shown in formula such as formula (1)；
N- (2- (1H- indoles -1- base) ethyl) -3- (2- ((4- methoxynaphthalene -1- base) methyl) -5- oxo pyrroles -2-
Base) propionamide, shown in structural formula such as formula (2)；
The present invention carries out further Determination of biological activity to the above-mentioned compound screened, finds above compound to hero
Hormone receptor has apparent antagonistic activity, and therefore, the present invention provides any of the above-described compound or pharmaceutically acceptable salt thereofs to prepare
Application in androgen receptor antagonists.
The research of the invention finds that: above-mentioned 2 compounds are in the experiment of the anti-prostate tumor of protein level and cellular level
Good effect is showed, therefore, the present invention provides any of the above-described compound or pharmaceutically acceptable salt thereofs to prepare prostate gland cancer cell
Application in antiblastic.
The present invention also provides any of the above-described compound or pharmaceutically acceptable salt thereofs to prepare answering in anti-prostate tumor drug
With.
The present invention also provides a kind of pharmaceutical composition, comprising as any compound of effective component or its is pharmaceutically acceptable
Salt.
Compound as effective component is androgen receptor antagonists, and therefore, pharmaceutical composition of the invention can be used as
There is the therapeutic agent of related disorders with androgen receptor.
The officinal salt be hydrochloride, phosphate, sulfate, acetate, maleate, citrate, benzene sulfonate,
Toluenesulfonate, fumarate or tartrate.
Described pharmaceutical composition further includes pharmaceutically acceptable excipient, diluent or carrier.It is specific as syrup, I
Primary glue and starch etc..The pharmaceutical composition can by vein, it is oral, sublingual, given through muscle or subcutaneous, skin and mucosa approach
Medicine.
The dosage form of described pharmaceutical composition is liquid preparation or solid pharmaceutical preparation.Specific such as tablet, capsule and injection
Agent etc..Each dosage form can be prepared with pharmacy conventional method.
It is that the present invention has the utility model has the advantages that
The present invention is based on the virtual screening methods of molecular docking and Determination of biological activity to find that 2 compounds swash hero
Plain receptor has apparent antagonistic activity, and disease related with androgen receptor can be applied to as androgen receptor antagonists
In disease treatment, the drug research for treatment prostate cancer at present provides new selection.
Detailed description of the invention
Fig. 1 be 13 compounds of the invention under the conditions of concentration is 10 μM to AR binding ability experimental result.
Fig. 2 is for compound 1 to AR binding ability experimental result under a series of concentration gradients.
Fig. 3 is for compound 3 to AR binding ability experimental result under a series of concentration gradients.
Fig. 4 is for compound 4 to AR binding ability experimental result under a series of concentration gradients.
Fig. 5 is that antagonist is mutual between combination conformation and antagonist in AR active pocket and AR active pocket residue
Binding mode, wherein (a) is that (albumen uses beam shapes to combination conformation of the antagonist in AR active pocket, and antagonist uses
Stick-like model is shown)；(b) Interactions Mode between antagonist and AR active pocket residue.
Fig. 6 be 13 compounds under the conditions of concentration is 10 μM to the antagonistic activity experimental result of AR.
Fig. 7 is for compound 5-7 to AR antagonistic ability experimental result under a series of concentration gradients.
Fig. 8 is for compound 8-10 to AR antagonistic ability experimental result under a series of concentration gradients.
Fig. 9 is for compound 11-13 to AR antagonistic ability experimental result under a series of concentration gradients.
Figure 10 is the rejection ability result that compound 1-8 is proliferated prostate gland cancer cell under the conditions of concentration is 10 μM.
Figure 11 is the rejection ability result that compound 9-13 is proliferated prostate gland cancer cell.
Specific embodiment
The present invention is further explained in the light of specific embodiments.
Embodiment 1
(1) based on the virtual screening of molecular docking
Experimental principle: molecular docking method is utilized, to the interaction between the compound and AR in compound database
It predicted, analyzed and is assessed, so that it is determined that the antagonist molecules that can be combined with AR.
Experimental method: forming the crystal structure (PDB number: 2PNU, 2Q7I and 3V49) of compound based on AR and androgen,
The research of virtual screening based on molecular docking has been carried out using the Glide module in Schrodinger molecular simulation software.Virtually
Compound library used by screening includes Chembridge, ChemDiv of latest edition and the packet of applicant seminar exploitation
Chinese herbal medicine effective ingredients three-dimensional structure database containing more than 60,000 a compounds.We are to optimal 2000 of virtual screening marking
Compound is evaluated using Reos rule, eliminates the molecule comprising reactive group.
Experimental result: molecular docking, which can be determined relatively accurately, can form organic small point compared with strong interaction with AR
Son.Prediction result based on molecular docking, we have purchased a compound more than 200 from commercial compound library, and after having carried out
It is continuous based on molecular level Binding experiment (PolarScreenTMAR Competitor Assay, Green, Thermo Fisher
Scientific active testing) therefrom has found that a batch has the small molecule compound of obvious AR antagonistic activity, is specifically shown in Table
1。
Table 1
The structural formula of above compound is as follows:
(2) AR competitive binding experiment
Experimental principle: the measurement of compound AR binding ability uses Invitrogen company (Thermo Fisher
Under Scientific) fluorescence polarization experiment.Androgen receptor { AR-LBD (His-GST) } and a kind of hero with fluorescence swash
Plain ligand (FluormoneTMAL Green) combines and forms binary complex (AR-LBD (His-GST)/FluormoneTMAL
Green), compound fluorescence polarization value with higher.This compound is added in the microwell plate containing test compound,
Tested compound replaces the fluorescent ligand (FluormoneTMAL in binary complex as a kind of competitiveness with cognition
Green), decline fluorescence polarization value.If what is be added is the noncompetitive ligand for not having replacement fluorescent chemicals ability,
Polarization value can still maintain high level.Therefore, after tested compound is added, the change of fluorescence polarization value can be used to quantitative survey
Tested compound is measured to the relative affinity of AR-LBD (His-GST).
Experimental method: after AR LBD albumen and high-affinity fluorescent ligand are mixed in buffer, various concentration is added
Test compound (virtual screening compound) using androgen dihydrotestosterone (DHT) as positive control).If testing compound pair
AR LBD has higher affinity, as a kind of competitiveness with the fluorescent ligand replaced in binary complex is known from experience, makes system
The decline of fluorescence polarization value；If the test compound being added is not bound with ability, the fluorescence polarization of system to AR LBD substantially
Value can still maintain high value, we can quantitative measurment using the variation of the fluorescence polarization value of multi-function microplate reader measurement system
Binding ability (binding affinity) of the virtual screening compound to AR.
Experimental result: as shown in Figure 1, the AR Percentage bound of 1-13 compound is more than 30%.We test various concentration
Compound and AR binding ability, discovery series compound has a good binding ability, the fluorescent ligand of AR inhibited to combine
503nhibiting concentration IC50To be micromole's rank, as shown in Figure 2,3, 4, wherein the IC of 1,3, No. 4 compound50Value is respectively
33 μM, 50-100 μM and 2.6 μM.
(3) between antagonist and AR Interactions Mode evaluation
Experimental principle: being based on molecular docking and molecular dynamics simulation, predicted from atomic scale AR antagonist and AR it
Between Interactions Mode.
Experimental procedure: based on molecular docking predict as a result, carrying out the molecular dynamics mould of 50ns to antagonist/AR
Quasi-, simulation uses AMBER14.
Experimental result: the phase interaction between antagonist and AR obtained by molecular docking prediction and molecular dynamics simulation
With as shown in Figure 5.Pre- geodesic structure shows that the molecular recognition between antagonist and AR mainly passes through Van der Waals and hydrogen bond phase interaction
With.Hydroxyl on antagonist can form stable hydrogen bond with Ser110；Two phenyl ring can be produced with multiple hydrophobic residues of surrounding
Raw strong Van der Waals interaction.
(4) AR antagonistic ability evaluation experimental
Experimental principle: AR as transcription factor, need with specific sequence, i.e. ARE response element, in conjunction with competence exertion turn
Record activity；Therefore it is enhanced green the reporter gene that ARR2PB promoter controls to be imported to the prostate gland cancer cell LNCaP of the AR positive
Color fluorescin EGFP, after various concentration tests compound drug treatment, the height for measuring the expression quantity of EGPF in cell is
Compound can be obtained to the power of AR antagonistic ability.
Experimental procedure: we with it is building in advance, containing there is the ARR that responds by force to AR2The EGFP of PB promoter control
(enhanced green fluorescence protein) reporter plasmid is obtained using the method for slow virus stable transfection LNCaP cell by AR tune
Expression EGFP prostate cancer cell line (LN-ARR is stablized in control2PB-EGFP)。LN-ARR2PB-EGFP cell first swashs without male
It is cultivated several days in the complete medium of element, so that background fluorescence activity is down to reduced levels, then by it with the density in 40000/hole
It is seeded in 96 saturating orifice plates of black bottom, after cytotostatic is adherent, while giving androgen and various concentration test compound
(virtual screening compound has listed the miscellaneous Shandong amine of antagonist pharmaceuticals grace), after being incubated for 24-48h, with multi-function microplate reader in wavelength
530nm wavelength fluorescence intensity level nearby is detected under 485nm exciting light, can quantitatively calculate test compound antagonism AR albumen
Inhibiting rate.
Experimental result:
As shown in fig. 6,1-13 compound can reach 30% or more inhibiting rate.
As Figure 7-9, after various concentration compound handles LN-ARR2PB-EGFP cell 36h, compound is to report
The expression of gene EGFP generates apparent downward effect, and dose-dependence is presented, this illustrates the compound cited by us
It is all active good potential AR antagonist.
(5) mtt assay detection compound anti-prostate tumor cell-proliferation activity
Experimental principle: the succinate dehydrogenase in living cells mitochondria can make exogenous MTT ((3- (4,5- dimethyl thiophenes
Azoles -2) -2,5- diphenyltetrazolium bromide bromide)) be reduced to bluish violet crystallization first a ceremonial jade-ladle, used in libation (Formazan) of water-insoluble and be deposited on
In cell, and the first a ceremonial jade-ladle, used in libation formed in buffer solution cell is added without this function in dead cell, is existed with enzyme-linked immunosorbent assay instrument
Its absorbance value is measured at 490nm wavelength, can reflect living cells quantity indirectly.
Experimental procedure: with being free of, androgen complete medium is thin in 96 orifice plate inoculated and cultured cancers with the density in 3000/hole
Born of the same parents, after cytotostatic is adherent, while give 1nM DHT and various concentration test compound (virtual screening compound has listed
Antagonist pharmaceuticals or DMSO), 10 μ L 5mg/ml MTT are added in every hole after being incubated for 4days, continue to be incubated in incubator
3hours, then 100 μ L SDS-HCl-PBS, tri- buffer is added in every hole, after 37 degree are incubated overnight, detects under microplate reader
Each hole absorbance value, is scaled survival rate at 570nM, can be obtained to the IC of drug compound50Value.
Experimental result: as shown in Figure 10,11, the compound on prostate cancer cell LNCaP in the present invention has apparent increasing
Rejection ability is grown, IC is inhibited50It can reach and the miscellaneous Shandong amine similar level of marketed drug grace.
Claims (7)
1. structural formula any compound or pharmaceutically acceptable salt thereof as shown in formula (1)~(2) is in preparing androgen receptor antagonists
Application,
2. any compound or pharmaceutically acceptable salt thereof as described in claim 1 is in preparing prostate gland cancer cell antiblastic
Using.
3. any compound or pharmaceutically acceptable salt thereof as described in claim 1 is preparing the application in anti-prostate tumor drug.
4. a kind of pharmaceutical composition, which is characterized in that include any compound as described in claim 1 as effective component
Or its officinal salt.
5. pharmaceutical composition as claimed in claim 4, which is characterized in that the officinal salt is hydrochloride, phosphate, sulfuric acid
Salt, acetate, maleate, citrate, benzene sulfonate, toluenesulfonate, fumarate or tartrate.
6. pharmaceutical composition as claimed in claim 4, which is characterized in that further include pharmaceutically acceptable excipient, dilution
Agent or carrier.
7. pharmaceutical composition as claimed in claim 4, which is characterized in that the dosage form of pharmaceutical composition be liquid preparation or
Solid pharmaceutical preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910125847.5A CN109700811B (en) | 2017-03-01 | 2017-03-01 | Indole acetamide structure type androgen receptor antagonist and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710117698.9A CN106943397B (en) | 2017-03-01 | 2017-03-01 | Androgen receptor antagonists and uses thereof |
| CN201910125847.5A CN109700811B (en) | 2017-03-01 | 2017-03-01 | Indole acetamide structure type androgen receptor antagonist and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710117698.9A Division CN106943397B (en) | 2017-03-01 | 2017-03-01 | Androgen receptor antagonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109700811A true CN109700811A (en) | 2019-05-03 |
| CN109700811B CN109700811B (en) | 2021-02-12 |
Family
ID=59468028
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910125993.8A Active CN109793737B (en) | 2017-03-01 | 2017-03-01 | Benzene sulfonamide structure type androgen receptor antagonist and application thereof |
| CN201910136005.XA Active CN109730996B (en) | 2017-03-01 | 2017-03-01 | Quinoline structure type androgen receptor antagonist and application thereof |
| CN201910125984.9A Active CN109846879B (en) | 2017-03-01 | 2017-03-01 | Androgen receptor antagonist with imine structure type and application thereof |
| CN201910125708.2A Pending CN109700798A (en) | 2017-03-01 | 2017-03-01 | Chromene flavones structure type androgen receptor antagonists and its application |
| CN201710117698.9A Active CN106943397B (en) | 2017-03-01 | 2017-03-01 | Androgen receptor antagonists and uses thereof |
| CN201910125983.4A Active CN109700794B (en) | 2017-03-01 | 2017-03-01 | Hydrazone structure type androgen receptor antagonist and application thereof |
| CN201910125847.5A Active CN109700811B (en) | 2017-03-01 | 2017-03-01 | Indole acetamide structure type androgen receptor antagonist and application thereof |
| CN201910125994.2A Active CN109793730B (en) | 2017-03-01 | 2017-03-01 | Benzopyran ring-closed chalcone structure type androgen receptor antagonist and application thereof |
| CN201910125838.6A Active CN109700804B (en) | 2017-03-01 | 2017-03-01 | Tetrahydrocarbazole structure type androgen receptor antagonist and application thereof |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910125993.8A Active CN109793737B (en) | 2017-03-01 | 2017-03-01 | Benzene sulfonamide structure type androgen receptor antagonist and application thereof |
| CN201910136005.XA Active CN109730996B (en) | 2017-03-01 | 2017-03-01 | Quinoline structure type androgen receptor antagonist and application thereof |
| CN201910125984.9A Active CN109846879B (en) | 2017-03-01 | 2017-03-01 | Androgen receptor antagonist with imine structure type and application thereof |
| CN201910125708.2A Pending CN109700798A (en) | 2017-03-01 | 2017-03-01 | Chromene flavones structure type androgen receptor antagonists and its application |
| CN201710117698.9A Active CN106943397B (en) | 2017-03-01 | 2017-03-01 | Androgen receptor antagonists and uses thereof |
| CN201910125983.4A Active CN109700794B (en) | 2017-03-01 | 2017-03-01 | Hydrazone structure type androgen receptor antagonist and application thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910125994.2A Active CN109793730B (en) | 2017-03-01 | 2017-03-01 | Benzopyran ring-closed chalcone structure type androgen receptor antagonist and application thereof |
| CN201910125838.6A Active CN109700804B (en) | 2017-03-01 | 2017-03-01 | Tetrahydrocarbazole structure type androgen receptor antagonist and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (9) | CN109793737B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111170943B (en) * | 2020-01-22 | 2021-03-26 | 浙江大学 | Benzo [ f ] cyclopentano [ c ] quinoline derivatives and use thereof |
| CN113101291A (en) * | 2021-04-14 | 2021-07-13 | 浙江大学 | Application of sulfonamide compound in preparation of medicine for treating autoimmune diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007116029A2 (en) * | 2006-04-07 | 2007-10-18 | Novartis Ag | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor |
| CN101885731A (en) * | 2009-05-14 | 2010-11-17 | 天津和美生物技术有限公司 | Thiophene derivative |
| CN104356192A (en) * | 2014-11-18 | 2015-02-18 | 中国药科大学 | Novel steroid androgen receptor inhibitors, and preparation method and medicinal application thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7009052B2 (en) * | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| DE10348022A1 (en) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases |
| CN100355744C (en) * | 2004-05-03 | 2007-12-19 | 深圳微芯生物科技有限责任公司 | Separation and extraction of flavone natural product active component for treating prostating disorders and medicinal preparation preparing and use thereof |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| MX2007015905A (en) * | 2005-06-24 | 2008-03-06 | Lilly Co Eli | Tetrahydrocarbazole derivatives useful as androgen receptor modulators. |
| BRPI0710191A2 (en) * | 2006-04-14 | 2012-06-05 | Astrazeneca Ab | compound or a pharmaceutically acceptable salt thereof, process for preparing it, and pharmaceutical composition |
| UY30699A1 (en) * | 2006-11-10 | 2008-07-03 | Astrazeneca Ab | SUBSTITUTED DERIVATIVES OF 4-PHENYLAMINE-QUINOLINA-3-CARBOXAMIDS, PHARMACEUTICALLY ACCEPTABLE SALTS, PREPARATION PROCESSES, COMPOSITIONS CONTAINING AND APPLICATIONS |
| US20100210692A1 (en) * | 2007-03-28 | 2010-08-19 | Farmer Stephen R | Methods of treatment using sirt modulators and compositions containing sirt1 modulators |
| US8268872B2 (en) * | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| JP2009286705A (en) * | 2008-05-27 | 2009-12-10 | Japan Health Science Foundation | Alkylcoumarins of new antitumor substance and use thereof |
| US20100035932A1 (en) * | 2008-08-07 | 2010-02-11 | Schepetkin Igor A | Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof |
| CN101624376B (en) * | 2009-08-19 | 2011-09-14 | 沈阳中海药业有限公司 | Substituted hydrazide compound and application thereof |
| US8809550B2 (en) * | 2009-09-10 | 2014-08-19 | Youzhi Tong | Androgen receptor antagonists and uses thereof |
| JP2014504269A (en) * | 2010-11-05 | 2014-02-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | Chemical compound |
| CN102093323B (en) * | 2010-12-09 | 2012-07-25 | 郑州大学 | Quercetin preparation method |
| ES2650744T3 (en) * | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Casein kinase 1 delta inhibitors (CK1delta) |
| WO2013076275A1 (en) * | 2011-11-23 | 2013-05-30 | The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv.Trinity Of Queen Elizabeth Near Dublin | Androgen receptor ligands |
| WO2013139929A1 (en) * | 2012-03-22 | 2013-09-26 | Ludwig-Maximilians-Universität München | Novel means and methods for treating diseases of the central nervous system, metabolic and cardiac diseases and aging |
| US9624211B2 (en) * | 2013-07-18 | 2017-04-18 | Board Of Regents, The University Of Texas System | Anti-cancer compounds |
| CN103768044B (en) * | 2014-01-18 | 2016-01-20 | 浙江大学 | Suppress the application of the reactive compound of DJ-1 dimerization |
| NZ711603A (en) * | 2014-02-07 | 2017-05-26 | Novogen ltd | Functionalised benzopyran compounds and use thereof |
| US9687469B2 (en) * | 2014-11-26 | 2017-06-27 | University Of Maryland, Baltimore | Agent containing flavonoid derivatives for treating cancer and inflammation |
| CN104940188A (en) * | 2015-06-24 | 2015-09-30 | 天津中医药大学 | Compound for treating and/or preventing estrogen associated diseases |
-
2017
- 2017-03-01 CN CN201910125993.8A patent/CN109793737B/en active Active
- 2017-03-01 CN CN201910136005.XA patent/CN109730996B/en active Active
- 2017-03-01 CN CN201910125984.9A patent/CN109846879B/en active Active
- 2017-03-01 CN CN201910125708.2A patent/CN109700798A/en active Pending
- 2017-03-01 CN CN201710117698.9A patent/CN106943397B/en active Active
- 2017-03-01 CN CN201910125983.4A patent/CN109700794B/en active Active
- 2017-03-01 CN CN201910125847.5A patent/CN109700811B/en active Active
- 2017-03-01 CN CN201910125994.2A patent/CN109793730B/en active Active
- 2017-03-01 CN CN201910125838.6A patent/CN109700804B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007116029A2 (en) * | 2006-04-07 | 2007-10-18 | Novartis Ag | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor |
| CN101885731A (en) * | 2009-05-14 | 2010-11-17 | 天津和美生物技术有限公司 | Thiophene derivative |
| CN104356192A (en) * | 2014-11-18 | 2015-02-18 | 中国药科大学 | Novel steroid androgen receptor inhibitors, and preparation method and medicinal application thereof |
Non-Patent Citations (3)
| Title |
|---|
| NATHAN A. LACK ET AL.: "Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening", 《J. MED. CHEM》 * |
| 甘露: "《雄激素受体拮抗剂-STN-1》", 24 May 2010 * |
| 甘露: "《雄激素受体拮抗剂-STN-2》", 27 October 2008 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109700804A (en) | 2019-05-03 |
| CN109700794A (en) | 2019-05-03 |
| CN109846879A (en) | 2019-06-07 |
| CN106943397A (en) | 2017-07-14 |
| CN109793737B (en) | 2021-06-29 |
| CN109700804B (en) | 2021-06-25 |
| CN109700798A (en) | 2019-05-03 |
| CN109793730A (en) | 2019-05-24 |
| CN109846879B (en) | 2021-06-29 |
| CN109700811B (en) | 2021-02-12 |
| CN109730996A (en) | 2019-05-10 |
| CN109730996B (en) | 2021-08-24 |
| CN109700794B (en) | 2021-01-08 |
| CN109793730B (en) | 2021-03-05 |
| CN109793737A (en) | 2019-05-24 |
| CN106943397B (en) | 2020-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Edmondson et al. | Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder | |
| Rao et al. | NMDA and AMPA receptors: old channels, new tricks | |
| TW200811140A (en) | Modulators of metabolism and the treatment of disorders related thereto | |
| TW200400822A (en) | New inhibitors of histone deacetylase | |
| TW200539867A (en) | Human g protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | |
| WO2011014825A2 (en) | Antiangiogenic small molecules and methods of use | |
| Staroń et al. | 5-HT1A receptor ligands and their therapeutic applications: review of new patents | |
| Arrang | Histamine and schizophrenia | |
| CN109700811A (en) | Indoleacetamide structure type androgen receptor antagonists and its application | |
| CN106414405A (en) | Treatment of cardiac remodeling and other heart conditions | |
| Gach et al. | α2δ1 dihydropyridine receptor subunit is a critical element for excitation-coupled calcium entry but not for formation of tetrads in skeletal myotubes | |
| CN108349900A (en) | Androgen receptor antagonists | |
| Deng et al. | Design, synthesis, and evaluation of dihydrobenzo [cd] indole-6-sulfonamide as TNF-α inhibitors | |
| JP4980418B2 (en) | Drug discovery target protein and target gene, and screening method | |
| Richelson | Neuroleptics and neurotransmitter receptors | |
| Riaposova et al. | Prostaglandin F2α requires activation of calcium-dependent signalling to trigger inflammation in human myometrium | |
| CN102964340B (en) | The selective dopamine D1 receptor stimulant of one class treatment alzheimer's disease | |
| Slassi et al. | Recent progress in 5-HT7 receptors: potential treatment of central and peripheral nervous system diseases | |
| Amani et al. | Docking Screens of Noncovalent Interaction Motifs of the Human Subtype-D2 Receptor–75 Schizophrenia Antipsychotic Complexes with Physicochemical Appraisal of Antipsychotics | |
| US20160146784A1 (en) | Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14 | |
| Guo et al. | Discovery of a natural PI3Kδ inhibitor through virtual screening and biological assay study | |
| Zhang et al. | Analysis of function role and long noncoding RNA expression in chronic heart failure rats treated with Hui Yang Jiu Ji decoction | |
| Niranjan et al. | Design of novel imidazopyrazine derivative against breast cancer via targeted NPY1R antagonist | |
| CN111170943B (en) | Benzo [ f ] cyclopentano [ c ] quinoline derivatives and use thereof | |
| Figueroa et al. | One hundred years of histamine research |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |